Video description: low-dose rapamycin and DNA damage in human T cells
The description presents a 2026 Oxford and Nottingham laboratory study reporting that low-dose rapamycin reduced DNA double-strand breaks by over 40% in human T cells under severe genotoxic stress, plus results from an attached 4-month placebo-controlled trial in older adults. [1]
Automatic summary · not editorially reviewed
The key findings
The description says the 2026 Oxford and Nottingham study reports low-dose rapamycin reduced DNA double-strand breaks by over 40% in human T cells under severe genotoxic stress. [1]
The description says this protective effect operates independently of autophagy. [1]
The description refers to an attached 4-month, placebo-controlled human trial (NCT05414292) in older adults. [1]
The source at a glance
- Study type / format
- Video description of a laboratory study and an attached placebo-controlled human trial
- Population / context
- Human T cells in laboratory experiments and older adults in an attached clinical trial, as described.
- Summary based on
- Creator description
- Original publication
- September 10, 2026
Rapamycin as direct genoprotector in T cells
According to the description, the 2026 study from the University of Oxford and the University of Nottingham reports a previously unrecognized mechanism: rapamycin acting as a direct genoprotector. In laboratory evidence, low-dose rapamycin reduced DNA double-strand breaks by over 40% in human T cells challenged with severe genotoxic stress. The description says this protective effect operates independently of autophagy. These are laboratory findings in human T cells, not evidence of longer human lifespan.
Supporting source [1]
Attached 4-month placebo-controlled trial in older adults
The description refers to an attached 4-month, placebo-controlled human trial (NCT05414292) in older adults. It says the trial data confirm significant target engagement, clearance of p21 senescence markers and reversal of inhibitory T-cell exhaustion markers (KLRG1 and NKG2A) without causing systemic immunosuppression. The description does not give participant numbers, doses or effect sizes for these trial results.
Supporting source [1]
Mannick trials and proposed applications
The description links these findings to the Mannick clinical trials and outlines translational applications in radioprotection and viral resilience. These are described as proposed applications, not established benefits. The description also includes commercial partner links and a disclaimer that the content is educational and not medical advice.
Supporting source [1]
How to interpret this
This is a video description; the video and transcript were not reviewed. Study details, participant numbers, doses and effect sizes are not given, and the described applications are proposals, not established benefits.
Based on the creator’s description; the full video and transcript were not analyzed.
Source & supporting passages
Modern Healthspan · youtube.com · September 10, 2026